Inactivated and live, attenuated poliovirus vaccines: mucosal immunity

  • R. W. Sutter
  • P. A. Patriarca


Both oral poliovirus vaccine (OPV) and inactivated poliovirus vaccine (IPV). induce some degree of mucosal immunity. However, OPV-induced mucosal immunity appears similar to that following natural exposure to wild poliovirus, while multiple doses of IPV may be necessary to induce measurable secretory antibody responses. Differences in mucosal immunity following vaccination with OPV and IPV are most pronounced in the intestine and least pronounced in the pharynx. Data on long-term persistence of mucosal antibodies are limited. However, long-term resistance to fecal and pharyngeal excretion is associated with high humoral antibody levels. Humoral immunity to poliovirus is strongly associated with individual protection against paralytic disease, while mucosal immunity decreases or eliminates fecal and pharyngeal excretion of polioviruses. Therefore, mucosal immunity is largely associated with community protection against circulation and transmission of poliovirus. To achieve the goal of eradication of poliomyelitis by the year 2000, strategies to amplify both mucosal immunity and humoral immunity are essential.


Mucosal Immunity Oral Poliovirus Vaccine Poliovirus Type Inactivate Poliovirus Vaccine Paralytic Poliomyelitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Institute of Medicine (1988) An evaluation of poliomyelitis vaccine policy options. Washington, DC: National Academy of Sciences (Publication No. IOM 88-04)Google Scholar
  2. 2.
    de Quadros CA, Andrus JK, Olive JM, de Macedo CG, Henderson DA (1992) Polio eradication from the Western Hemisphere. Ann Rev Publ Health 13: 239–252CrossRefGoogle Scholar
  3. 3.
    Ogra PL, Karzon DT (1971) Formation and function of poliovirus antibody in different tissues. Prog Med Virol 13: 156–193Google Scholar
  4. 4.
    Paul JR, Riordan JT, Melnick JL (1951) Antibodies to three different antigenic types of poliomyelitis virus in sera from North Alaskan Eskimos. Am J Hygiene 54: 275–285Google Scholar
  5. 5.
    Sabin AB (1952) Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus. J Experiment Med 96:99–106CrossRefGoogle Scholar
  6. 6.
    Salk J (1956) Requirements for persistent immunity to poliomyelitis. Trans Assn Am Phys 69: 105–114Google Scholar
  7. 7.
    Hammon WM, Ludwig EH (1957) Possible protective effect of previous type 2 infection against paralytic poliomyelitis due to type 1 virus. Am J Hygiene 66: 274–280Google Scholar
  8. 8.
    Owen RL, Jones AL (1974) Epithelial cell specialization within human Peyer’s patches: an ultrastructural study of intestinal lymphoid follicles. Gastroenterology 66: 189–203PubMedGoogle Scholar
  9. 9.
    Sicinski P, Rowinski J, Warchol JB, Jarzabek Z, Gut W, Szczyiel B, Bielecki K, Koch G (1990) Poliovirus type 1 enters the human host through intestinal M cells. Gastroenterology 98:56–58PubMedGoogle Scholar
  10. 10.
    Owen RL (1977) Sequential uptake of horseradish peroxidase by lymphoid follicle epi thelium of Peyer’s patches in the normal unobstructed mouse intestine: an ultrastructural study. Gastroenterology 72: 440–451PubMedGoogle Scholar
  11. 11.
    Dhar R, Ogra PL (1985) Local immune responses. Brit Med Bull 41: 28–33PubMedGoogle Scholar
  12. 12.
    Mendelsohn CL, Wimmer E, Racaniello VR (1989) Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56: 855–865PubMedCrossRefGoogle Scholar
  13. 13.
    Mestecky J, McGhee JR, Michalek SM, Arnold RR, Crago SS, Babb JL (1978) Concept of local and common mucosal immune response. In: McGhee JR, Mestecky J, Babb JL (eds) Secretory immunity and infection. Proceedings of the International Symposium on the Secretory Immune System and Caries Immunity. Plenum Press, New York, pp 185–192Google Scholar
  14. 14.
    Mestecky J ,McGhee JR, Crago SS, Jackson S, Kilian M, Kiyono H, Babb JL, Michalek SM (1980) Molecular-cellular interactions in the secretory IgA response. J Reticulo endothelSoc 28: 45–60Google Scholar
  15. 15.
    Losonsky GA, Fishaut JM, Stussenberg J, Ogra PL (1982) Effect of immunization against rubella in lactation products. I. Development and characterization of specific immunologic reactivity in breast milk. J Inf Dis 145: 654–660CrossRefGoogle Scholar
  16. 16.
    Bogger-Goren S, Baba K, Hurley P, Yabuuchi H, Takahashi M, Ogra PL (1982) Anti body response to varicella-zoster virus after natural or vaccine-induced infection. J Inf Dis 146; 260–265CrossRefGoogle Scholar
  17. 17.
    Wang K, Sun L, Jubelt B, Waltenbaugh C (1989) Cell-mediated immune responses to poliovirus. I. Conditions for induction ,characterization of effector cells ,and crossreactivity between serotypes for delayed hypersensitivity and T cell proliferative responses. Cell Immunol 119: 252–262PubMedCrossRefGoogle Scholar
  18. 18.
    Inouye S ,Matsuno S ,Yamaguchi H (1984) Efficient coating of the solid phase with rotavirus antigens for enzyme-linked immunosorbent assay of immunoglobulin A antibody in feces. J Clin Microbiol 19: 259–263PubMedGoogle Scholar
  19. 19.
    Losonsky GA ,Renneis MB ,Lim Y ,Krall G ,Kapikian AZ ,Levine MM (1988) Systemic and mucosal immune response to rhesus rotavirus vaccine MMU 18006. Pediatr Infect Dis J 7:388–393PubMedCrossRefGoogle Scholar
  20. 20.
    Nishio O ,Ishihara Y ,Sakae K ,Nonmura Y ,Kuno A ,Yasukawa S ,Inoue H ,Miyamura K ,Kono R (1984) The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: Follow-up of vaccinees for 10 years. J Biol Stand 12: 1–10PubMedCrossRefGoogle Scholar
  21. 21.
    Ogra PL ,Karzon DT ,Righthand F ,MacGillivray M (1968) Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N Engl J Med 279: 893–900PubMedCrossRefGoogle Scholar
  22. 22.
    Keller R ,Dwyer J (1968) Neutralization of poliovirus by IgA coproantibodies. J Immunol 101: 192–202PubMedGoogle Scholar
  23. 23.
    Keller R ,Dwyer J ,Oh W ,D’Amodio M (1969) Intestinal IgA neutralizing antibodies in newborn infants following poliovirus immunization. Pediatrics 43: 330–338PubMedGoogle Scholar
  24. 24.
    Berger R ,Ainbender E ,Hodes HL ,Zepp HD ,Hevizy MM (1967) Demonstration of IgA polio antibody in saliva ,duodenal fluid ,and urine. Nature (London) 214: 420–422CrossRefGoogle Scholar
  25. 25.
    Zhaori G ,Sun M ,Ogra PL (1988) Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines. J Infect Dis 158: 160–165PubMedCrossRefGoogle Scholar
  26. 26.
    Onorato IM ,Modlin JF ,McBean AM ,Thoms ML ,Losonsky GA ,Bernier RH (1991) Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 163: 1–6PubMedCrossRefGoogle Scholar
  27. 27.
    Faden H, Modlin JF, Thoms ML ,McBean AM ,Ferdon MB ,Ogra PL (1990) Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: Systemic and local immune responses. J Infect Dis 162: 1291–1297PubMedCrossRefGoogle Scholar
  28. 28.
    Lepow ML ,Warren RJ ,Gray N ,Ingram VG ,Robbins (1961) Effect of Sabin type 1 poliomyelitis vaccine administered by mouth to newborn infants. N Engl J Med 264: 1071–1078PubMedCrossRefGoogle Scholar
  29. 29.
    Pagano JS ,Plotkin SA ,Koprowski H (1960) Variation of response in early life to vaccination with living attenuated poliovirus and lack of immunologic tolerance. Lancet i: 1224–1226CrossRefGoogle Scholar
  30. 30.
    John TJ (1984) Immune response of neonates to oral poliomyelitis vaccine. Brit Med J 289: 881CrossRefGoogle Scholar
  31. 31.
    Svennerholm AM ,Hanson LA ,Holmgren J,Jalil F ,Lindblad BS ,Khan SR ,Nilsson A ,Svennerholm B (1981) Antibody response to live and killed poliovirus vaccines in the milk of Pakistani and Swedish women. J Infect Dis 143: 707–711PubMedCrossRefGoogle Scholar
  32. 32.
    Hanson LA, Carlsson B, Jalil F, Lindblad BS, Khan SR, van Wezel AL (1984) Different secretory IgA antibody responses after vaccination with inactivated and live poliovirus vaccines. Rev Infect Dis 6 [Suppl]: 356–360CrossRefGoogle Scholar
  33. 33.
    Gelfand HM, LeBlanc DR, Fox JP, Conwell DP (1957) Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. Am J Hygiene 65:367–385Google Scholar
  34. 34.
    Marine WM, Chin TDY, Gravelle CR (1962) Limitation of fecal and pharyngeal excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. AmJ Hygiene 76: 173–195Google Scholar
  35. 35.
    Glezen WP, Lamb GA, Beiden EA, Chin TDY (1966) Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. Am J Epidemiol 53: 224–237Google Scholar
  36. 36.
    Ghendon YUZ, Sanakoyeva II (1961) Comparison of the resistance of the intestinal tract to poliomyelitis vaccine (Sabin’s strains) in persons after naturally and experimentally acquired immunity. Acta Virol (Praha) 5: 265–273Google Scholar
  37. 37.
    Henry JL, Jaikaran ES, Davies JR, Thomlinson AJH, Mason PJ, Barnes JM, Beale AJ (1966) A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hygiene (Cambridge) 64: 105–120CrossRefGoogle Scholar
  38. 38.
    Savilahti E, Klemola T, Carlsson B, Mellander L, Stenvik M, Hovi T (1988) Inadequacy of mucosal IgM antibodies in selective IgA deficiency: Excretion of attenuated polio viruses is prolonged. J Clin Immunol 8: 89–94PubMedCrossRefGoogle Scholar
  39. 39.
    Mellander L, Björkander J, Carlsson B, Hansson LA (1985) Serum and secretory antibodies in IgA deficient and immunosuppressed individuals. J Clin Immunol 4: 284–291Google Scholar
  40. 40.
    Savilahti E (1973) IgA deficiency in children. Immunoglobulin-containing cells in the intestinal mucosa, immunoglobulins in secretions and IgA levels. Clin Exp Immunol 13:395–406PubMedGoogle Scholar
  41. 41.
    Smith JWG, Lee JA, Fletcher WB, Morris CA, Parker DA, Yetts R, Magrath DI, Perkins FT (1976) The response to oral poliovaccine in persons aged 16–18 years. J Hygiene (Cambridge) 76: 235–247CrossRefGoogle Scholar
  42. 42.
    Ogra PL (1970) Distribution of echovirus antibody in serum, nasopharynx, rectum and spinal fluid after natural infection with echovirus type 6. Infection Immunol 2: 150–155Google Scholar
  43. 43.
    Hovi T, Huovilainen A, Kuronen T, Poyry T, Salama N, Cantell K, Kinnunen E, Lapinleimu K, Roivainen M, Stenvik M (1986) Outbreak of paralytic poliomyelitis in Finland: Widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet i: 1427–1432CrossRefGoogle Scholar
  44. 44.
    Centers for Disease Control (1986) Update: Poliomyelitis outbreak -Finland, 1984–1985. MMWR 35: 82–86Google Scholar
  45. 45.
    Icenogle JP, Minor PD, Ferguson M, Hogle JM (1986) Modulation of humoral response to a 12-amino acid site on the poliovirus. J Virology 60: 297–301PubMedGoogle Scholar
  46. 46.
    Roivainen M, Hovi T (1987) Intestinal trypsin can significantly modify antigenic properties of polioviruses: implication for the use of inactivated poliovirus vaccine. J Virology 61: 3749–3753PubMedGoogle Scholar
  47. 47.
    Zhaori G, Sun M, Faden HS, Ogra PL (1989) Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines. J Infect Dis 159: 1018–1024PubMedCrossRefGoogle Scholar
  48. 48.
    Ogra P (1970) The role of nasopharyngeal tonsils and adenoids in the mechanism of mucosal immunity to poliovirus. American Pediatric Society, 80th Annual Meeting, Program and AbstractsGoogle Scholar
  49. 49.
    Aycock WL (1942) Tonsillectomy and poliomyelitis. I. Epidemiologie considerations. Medicine 21: 65–94CrossRefGoogle Scholar
  50. 50.
    Melnick JL, Proctor RO, Ocampo AR, Diwan AR, Ben-Porath E (1966) Free and bound virus in serum after administration of oral poliovirus vaccine. AmJ Epidemiol 84: 329–342Google Scholar
  51. 51.
    Janda Z, Adam E, Vonka V (1967) Properties of a new type 3 attenuated poliovirus. VI. Alimentary tract resistance in children fed previously with type 3 Sabin vaccine to rein-fection with homologous and heterologous type 3 attenuated poliovirus, Arch Virusfor schung 20: 87–98CrossRefGoogle Scholar
  52. 52.
    Isacson P, Melnick JL, Walton M (1957) Environmental studies of endemic enteric viral infections. II. Poliovirus infections in household units. Am J Hygiene 65: 29–42Google Scholar
  53. 53.
    Salk JE (1959) Preconceptions about vaccination against paralytic poliomyelitis. Ann Intern Med 50: 843–861PubMedGoogle Scholar
  54. 54.
    Lapinleimu K (1984) Elimination of poliomyelitis in Finland. Rev Infect Dis 6 [Suppl]: 457–460CrossRefGoogle Scholar
  55. 55.
    Böttiger M (1984) Long-term immunity following vaccination with killed poliovirus vaccine in Sweden, a country with no circulating poliovirus. Rev Infect Dis 6 [Suppl]: 548–551CrossRefGoogle Scholar
  56. 56.
    Sutter RW, Patriarca PA, Brogan S, Malankar PG, Pallansch PA, Kew OM, Bass AG, Cochi SL ,Alexander JP, Hall DB, Suleiman AJM, Al-Ghassani AAK, El-Bualy MS (1991) Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children. Lancet 338: 715–720PubMedCrossRefGoogle Scholar
  57. 57.
    Otten MW, Deming MS, Jaiteh KO, Flagg EW, Forgie I, Sanyang Y, Sillah B, Brogan D, Gowers P (1992) Epidemic poliomyelitis in The Gambia following the control of poliomyelitis as an endemic disease. I. Descriptive findings. Am J Epidemiol 135: 381–392PubMedGoogle Scholar
  58. 58.
    Deming MS, Jaiteh KO, Otten MW, Flagg EW, Jaallow M, Cham M, Brogan D, N’jie H (1992) Epidemic poliomyelitis in The Gambia following the control of poliomyelitis as an endemic disease. II. Clinical efficacy of trivalent oral polio vaccine. Am J Epidemiol 135: 393–408PubMedGoogle Scholar
  59. 59.
    Patriarca PA, Wright PF, John TJ (1991) Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 13: 926–939PubMedCrossRefGoogle Scholar
  60. 60.
    McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R, The Field Staff and Coordinating Committee (1988) Serologic response to oral polio vaccine and enhanced potency inactivated polio vaccines. Am J Epidemiol 128: 615–628PubMedGoogle Scholar
  61. 61.
    Patriarca PA, Laender F, Palmeira G, Couto Oliveira MJ, Lima Filho J, de Souza Dantes MC, Tenorio Cordeiro M, RisiJB, Orenstein WA (1988) Randomized trial of alternative formulations of oral poliovaccine in Brazil. Lancet i: 429–432CrossRefGoogle Scholar
  62. 62.
    Expanded Programme on Immunization, Pan American Health Organization (1990) Surveillance of wild poliovirus in the Americas. EPI Newsletter 12: 1–3Google Scholar
  63. 63.
    Expanded Programme on Immunization (1992) Progress towards poliomyelitis eradication. Philippines. Weekly Epidemiol Rec 67: 205–208Google Scholar
  64. 64.
    World Health Organization (1988) Global eradication of poliomyelitis by the year 2000. Weekly Epidemiol Rec 63: 161–162Google Scholar
  65. 65.
    Carlson B, Zaman S, Mellander L, Jalil F, Hanson LA (1985) Secretory and serum immunoglobulin class-specific antibodies to poliovirus after vaccination. J Infect Dis 152:1238–1244CrossRefGoogle Scholar
  66. 66.
    Sabin AB, Michaels RH, Ziring P, Krugman S, Warren J (1963) Effect of oral poliovirus vaccine in newborn children. II. Intestinal resistance and antibody response at 6 months in children fed type 1 vaccine at birth. Pediatrics 31:641–650PubMedGoogle Scholar
  67. 67.
    Ogra PL, Karzon DT, Righthand F, MacGillivray M (1968) Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N Engl J Med 279: 893–900PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1993

Authors and Affiliations

  • R. W. Sutter
    • 1
  • P. A. Patriarca
    • 1
  1. 1.Division of ImmunizationCenters for Disease Control and PreventionAtlantaUSA

Personalised recommendations